- Home
- TXO vs GYRE Comparison
TXO vs GYRE Comparison
Compare TXO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- GYRE
- Stock Information
- Founded
- TXO 2012
- GYRE 2002
- Country
- TXO United States
- GYRE United States
- Employees
- TXO N/A
- GYRE N/A
- Industry
- TXO Oil & Gas Production
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- GYRE Health Care
- Exchange
- TXO Nasdaq
- GYRE Nasdaq
- Market Cap
- TXO 701.2M
- GYRE 755.7M
- IPO Year
- TXO 2023
- GYRE N/A
- Fundamental
- Price
- TXO $13.06
- GYRE $7.55
- Analyst Decision
- TXO Strong Buy
- GYRE Strong Buy
- Analyst Count
- TXO 2
- GYRE 2
- Target Price
- TXO $20.50
- GYRE $17.00
- AVG Volume (30 Days)
- TXO 151.4K
- GYRE 58.1K
- Earning Date
- TXO 11-04-2025
- GYRE 11-07-2025
- Dividend Yield
- TXO 18.40%
- GYRE N/A
- EPS Growth
- TXO N/A
- GYRE N/A
- EPS
- TXO 0.36
- GYRE 0.04
- Revenue
- TXO $364,412,000.00
- GYRE $107,265,000.00
- Revenue This Year
- TXO $32.13
- GYRE $15.25
- Revenue Next Year
- TXO $11.48
- GYRE $33.14
- P/E Ratio
- TXO $36.42
- GYRE $195.96
- Revenue Growth
- TXO 27.66
- GYRE 2.13
- 52 Week Low
- TXO $12.61
- GYRE $6.11
- 52 Week High
- TXO $20.70
- GYRE $14.42
- Technical
- Relative Strength Index (RSI)
- TXO 41.54
- GYRE 46.16
- Support Level
- TXO $13.15
- GYRE $7.82
- Resistance Level
- TXO $14.09
- GYRE $8.47
- Average True Range (ATR)
- TXO 0.33
- GYRE 0.36
- MACD
- TXO 0.01
- GYRE -0.00
- Stochastic Oscillator
- TXO 19.36
- GYRE 34.74
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.